miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-κB in high-grade serous ovarian carcinoma

被引:0
|
作者
Yuqiong Wang
Xiyu Zhang
Wei Tang
Zhenghong Lin
Limei Xu
Ruifen Dong
Yinuo Li
Jieyin Li
Zaixin Zhang
Xiangzhi Li
Ling Zhao
Jian-Jun Wei
Changshun Shao
Beihua Kong
Zhaojian Liu
机构
[1] Shandong University School of Medicine,Department of Cell Biology
[2] Qilu Hospital,Department of Obstetrics and Gynecology
[3] Shandong University,Department of Molecular Medicine and Genetics
[4] Shandong University School of Medicine,Department of Pathogenic Biology
[5] Shandong University School of Medicine,Department of Pathology
[6] School of life Science,undefined
[7] Chongqing University,undefined
[8] Northwestern University School of Medicine,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Activation of mammalian target of rapamycin (mTOR) signaling pathway is associated with poor prognosis of epithelial ovarian cancer. The TSC1-TSC2 complex is a critical negative regulator of mTOR signaling. Here, we demonstrated that TSC1 was frequently downregulated in high-grade serous ovarian carcinoma (HGSOC) and low TSC1 expression level is associated with advanced tumor stage. We next identified miR-130a to be a negative regulator of TSC1 by targeting its 3’UTR. miR-130a was overexpressed in HGSOC and could drive proliferation and invasion/metastasis of ovarian cancer cells. miR-130a could also attenuate rapamycin/starvation-induced autophagy. Ectopic TSC1 expression could block the effects of miR-130a on cell proliferation, migration and autophagy. Finally, we found that miR-130a expression could be upregulated by inflammatory factors and was transactivated by NF-κB. Therefore, our findings establish a crosstalk between inflammation and mTOR signaling that is mediated by miR-130a, which might have a pivotal role in the initiation and progression of HGSOC.
引用
收藏
页码:2089 / 2100
页数:11
相关论文
共 50 条
  • [1] miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-κB in high-grade serous ovarian carcinoma
    Wang, Yuqiong
    Zhang, Xiyu
    Tang, Wei
    Lin, Zhenghong
    Xu, Limei
    Dong, Ruifen
    Li, Yinuo
    Li, Jieyin
    Zhang, Zaixin
    Li, Xiangzhi
    Zhao, Ling
    Wei, Jian-Jun
    Shao, Changshun
    Kong, Beihua
    Liu, Zhaojian
    CELL DEATH AND DIFFERENTIATION, 2017, 24 (12): : 2089 - 2100
  • [2] TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
    Gonghua Qi
    Hanlin Ma
    Yingwei Li
    Jiali Peng
    Jingying Chen
    Beihua Kong
    Cell Death & Disease, 12
  • [3] TREATMENT OF TSC1-DELETED HIGH-GRADE SEROUS OVARIAN CANCER CONFOUNDED BY HEDGEHOG PATHWAY OVEREXPRESSION
    Ho, Gwo Yaw
    Lieschke, Elizabeth
    Kyran, Elizabeth
    Shield-Artin, Kristy
    Kondrashova, Olga
    Holian, Robert
    Singh, Ankita
    Phuong, Thuan
    Cazet, Aurelie
    Swarbrick, Alex
    Bowtell, David
    Wakefield, Matthew J.
    Scott, Clare
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 112 - 113
  • [4] TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
    Qi, Gonghua
    Ma, Hanlin
    Li, Yingwei
    Peng, Jiali
    Chen, Jingying
    Kong, Beihua
    CELL DEATH & DISEASE, 2021, 12 (12)
  • [5] miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma
    Dong, Ruifen
    Liu, Xiaolin
    Zhang, Qing
    Jiang, Zhijun
    Li, Yingwei
    Wei, Yuyan
    Li, Yinuo
    Yang, Qifeng
    Liu, Jinsong
    Wei, Jian-Jun
    Shao, Changshun
    Liu, Zhaojian
    Kong, Beihua
    ONCOTARGET, 2014, 5 (21) : 10816 - 10829
  • [6] Interferon-stimulated Gene, 15 kDa (ISG15) in Ovarian High-grade Serous Carcinoma: Prognostic Impact and Link to NF-κB Pathway
    Darb-Esfahani, Silvia
    Sinn, Bruno V.
    Rudl, Marc
    Sehouli, Jalid
    Braicu, Ioana
    Dietel, Manfred
    Denkert, Carsten
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2014, 33 (01) : 16 - 22
  • [7] DEREGULATION AND POTENTIAL THERAPEUTIC TARGETING OF THE NF-κB PATHWAY IN HIGH-GRADE CHILDHOOD BRAIN TUMORS
    Van Vuurden, D. G.
    Hulleman, E.
    Van der Stoop, P. M.
    Gupta, R.
    Wedekind, L. E.
    Badr, C. E.
    Meijer, D. H.
    Noske, D. P.
    Wurdinger, T.
    Kaspers, G. J. L.
    Cloos, J.
    NEURO-ONCOLOGY, 2010, 12 (06) : II50 - II50
  • [8] The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma
    Chesnokov, Mikhail
    Yousif, Abdelrahman
    Chefetz, Ilana
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [9] The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma
    Chesnokov, Mikhail S.
    Khan, Imran
    Park, Yeonjung
    Ezell, Jessica
    Mehta, Geeta
    Yousif, Abdelrahman
    Hong, Linda J.
    Buckanovich, Ronald J.
    Takahashi, Akimasa
    Chefetz, Ilana
    CANCERS, 2021, 13 (06) : 1 - 20
  • [10] Protein tyrosine phosphatase L1 inhibits high-grade serous ovarian carcinoma progression by targeting IκBα
    Wang, Yacheng
    Li, Miao
    Huang, Ting
    Li, Jun
    ONCOTARGETS AND THERAPY, 2018, 11 : 7603 - 7612